

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated 30 November 2020 (the “**Prospectus**”) issued by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered. The Company has not been and will not be registered under the U.S. Investment Company Act of 1940, as amended.*

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.



和鉑醫藥控股有限公司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

UPDATE ON COLLABORATION WITH ABBVIE AND UTRECHT UNIVERSITY FOR CO-DEVELOPMENT OF HBM9022

On 3 December 2020 (Hong Kong time), AbbVie Inc. (NYSE:ABBV) (“**AbbVie**”), Harbour Antibodies B.V. (“**Harbour Antibodies**”, a direct wholly-owned subsidiary of the Company) and Utrecht University Holding B.V. and Universiteit Utrecht (Utrecht University or “**UU**”) entered into a license agreement (the “**License Agreement**”) for the advancement of the development of the fully human, COVID-19 neutralizing antibody 47D11 (“**HBM9022 (ABBV-47D11)**”), which was co-discovered by UU and Erasmus University Medical Center Rotterdam (“**Erasmus Medical Center**”) using our Harbour antibody platforms.

Under the License Agreement, AbbVie will conduct clinical development of HBM9022 (ABBV-47D11), and if successful, will manufacture and commercialize the product worldwide. AbbVie (as licensee) will pay Harbour Antibodies and UU (as licensors) a one-off license fee, milestone payments and tiered royalties on net sales upon successful commercialization.

The Group has collaborated with AbbVie, UU and Erasmus Medical Center since June 2020, as disclosed in the Prospectus on pages 301 and 302. The collaboration aims to develop HBM9022 (ABBV-47D11) to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus. HBM9022 (ABBV-47D11) is one of the Company’s pre-clinical stage assets and is not related to any of our Core Products (as defined in the Prospectus).

Erasmus Medical Center entered into a patent transfer agreement with UU and Harbour Antibodies on 26 November 2020 whereby it assigned to UU its right, title and interest to patents underlying HBM9022 (ABBV-47D11), and granted UU and Harbour Antibodies the right to grant an exclusive license to AbbVie. Erasmus Medical Center is not a party to the License Agreement.

The Directors confirm that all material information relevant to the Global Offering and the Group has been disclosed in the Prospectus in accordance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance, the Securities and Futures (Stock Market Listing) Rules and the Listing Rules. The Directors consider that the update outlined above does not constitute material information that would require issuance of a supplemental prospectus under Rule 11.13 of the Listing Rules. Accordingly, the listing timetable shall remain unchanged with listing expected to take place on Thursday, 10 December 2020.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman

Hong Kong, 8 December 2020

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang, Dr. Mai-Jing Liao, and Dr. Atul Mukund Deshpande as executive Directors; Mr. Yu Min Qiu and Mr. Junfeng Wang as non- executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Ms. Weiwei Chen as independent non-executive Directors.